We report results of a quality-control survey of radioimmunoassay (RIA) of eight analytes, participated in by 249 laboratories of various types throughout Japan. For the purpose of the external control survey, lyophilized specimens containing two different concentrations of each analyte were sent to the participating laboratories, which supplied both their assay values and their raw data for the standard curves and for the samples. The individual data for the standard curve were analyzed by the RIA data-processing program described by Faden and Rodbard. The precision profile obtained for the individual assay was used as the estimate of the quality of each assay. Although there was a wide scatter in assay values, the quality of the assay by the individual laboratorieswas not the major contributorto this scattering, because the values they reported for the assays and precision profiles of the standard curves were almost identical with those obtained from the kit manufacturers. When the reported assay values were analyzed according to the brand of kits, by analysis of variance, the treatment mean square due to differencein the make of the kitssignificantlyexceededthe error mean square due to "within-kit" variation in the assay of insulin, thyroxin, thyrotropin, cortisol, gastrin, and digoxin. The CVs for "between-kit," "within-kit," "between-assay" and "within-assay"variations (the latter two aspects were studied in a representative laboratory, for convenience of comparison) were about 20, 15, 13, and 7%, respectively. Because the observed within-kit variation is of almost the same magnitude as that expected from the combination of within-assay and between-assay variation, the skill of the users probably was equal and the accuracy and precision of the kits probably had the greatest impact on assay variation. This survey also emphasizes the criteria for commercially available AlA kits.
in detail. This study was also expected to provide an inventory of a number of objective criteria of the quality of the kits.
Materials and Methods
So we could determine appropriate concentrations of the analytes for quality-control specimens, we analyzed standard curves for each RIA done with the commercially available kits by the RIA-data processing program described by Faden and Rodbard (1). This program gave the magnitude of variation along the standard curve, in the form of a "precision proffle." Two concentrations of each substance were selected from the middle portion of the standard curves obtained with commercially available kits, so as to obtain a meaningful value representative of the precision of each kit (2) . At these concentrations, the predicted CVs were minimal. To make quality-control specimens, standards were dissolved in a medium comprising an artificial protein mixture with concentrations akin to those in serum (Table  1) , provided from Bio-RIA, Canada. Mindful of the profound effect of serum protein on RIA results, we took special precautions that protein concentrations should closely approximate those in normal serum (footnote to Table 1 ). All the quality-control specimens thus prepared were lyophilized and delivered to the participating laboratories, along with detailed instructions for their reconstitution.
The participating laboratories were requested to return to us their assay values for samples A (higher concentration) and B (lower concentration). Also, the standard-curve data they obtained were reported to us and analyzed by use of the program described by Faden and Rodbard (1). The assay values received from the laboratories, those from the dataprocessing program, and the precision proffle of each assay were compared statistically by means of one-way analysis of variance, comparing treatment mean square due to difference in kits with error mean square, from which "withinkit" variation was derived.
The cause of scatter was divided into "between-kit" and "within-kit" variations (2) . "Within-kit" variation, in terms of CV, was derived from square root of "error mean square" (EMS) divided by the grand mean. "Between-kit" variation, in terms of CV, was derived from the standard deviation of the kit means divided by the grand mean. Component of between-kit variation was calculated from treatment mean square, assuming the average number assigned to treatment as described either by Snedecor and Cochran (4) or by Rodbard (3). We adopted the latter because of the uneven distribution of the number of samples assigned to the kits.
To assess the "within-assay"
and "between-assay" varia- tions, for comparison, we obtained, from a representative institution, at least 10 sequential assay data for a qualitycontrol specimen having a concentration almost identical with that of sample A. The within-assay and between-assay variations, together with the "component of between-assay" variation, were calculated as described by Rodbard (4) and expressed in terms of CV. The pattern of the frequency distribution of the predicted CV from the precision profile was not a gaussian but a Poisson distribution, presumably owing to the fact that the predicted CV would not be smaller than a certain minimal value because factors such as pipetting error and incomplete separation of bound from free are inherent in the assay procedure. We statistically compared the predicted CV after transformation of the CV value to arc-sine, the distribution of which was proven to be normal. 
Results

Insulin
units/L (kit a)
. Those values, obtained from standard curves manually drawn by the participating laboratories, were not different from those obtained by computerized data-processing. Regarding the assay values for samples A and B, the treatment mean square significantly exceeded the error mean square from which the within-kit variation was derived. It indicates that the variation due to difference in kit is statistically significant. Although the between-kit variation was calculated as an indicator of the magnitude of the variation ascribable to differences in kits, this indicator is sometimes erratic because of the relatively small number of different brands of kits. In fact, for sample B the betweenkit variation is smaller than the within-kit variation, while the analysis of variance showed that the treatment mean square due to difference in kits is significantly larger than the error mean square by F test.
For comparison, the within-assay and between-assay variations in insulin RIA with kit a were calculated by Rodbard's method (4) and included in The within-assay and between-assay CVs for sample A as measured with kit c were 3.6% (for a singleton, i.e., for a single tube) and 11.3%, respectively ( Table 3 ). The betweenkit CV for this assay was considerably smaller than that reported previously (23%) by Gordon et al. (5) .
The predicted CV from the precision proffle ranged from 5.3 to 13.3% at the intercept of sample A and from 7.4 to 14.0% for sample B. The predicted CV obtained from the participating laboratories was not statistically different from that reported by the manufacturers (parenthesized in Table 3 ). 
Thyrotropin (TSH)
Gastrin
38.2%
8.8%
See the footnotes to Tables 8 and 9 , the two brands of kits provided almost identical results, as would be expected.
Discussion
The present results reveal the state of the art of some kits currently available in Japan. Before the survey, we anticipated the following three factors as contributory to the variation of assay values: (a) inappropriate curve fitting, (b) poor quality of the assay (a large predicted CV in the precision profile), and (c) difference in the accuracy of different kits. With the aid of a data-processing program, it was possible to determine the magnitude of the contribution of these factors to the overall variation in the assay results.
Comparison of the assay value of quality-control samples Table 10 summarizes the results. The summation of the variation withinassay and between-assay is almost equal to the observed within-kit variation. Thus, it is probable that the technical skill of the users was equal and that differences in the quality of kits had the greatest impact on assay variation in Japan.
Values reported by laboratories
The contribution of differences in the kits to the overall variation has two components: differences in accuracy and differences in precision. The difference in accuracy among the kits was typically demonstrated in insulin RIA, in which kit a gave the highest value for sample A (66.5 ± 6.7 millimt.units/L), while kit d gave the lowest value (41.0 ± 5.6 milli-int. unitsfL) for the same sample. As reported previously, this difference in results for insulin with RIA kits resulted from a difference in potency of the standards (7) . The difference in precision among the kits was also typically demonstrated in insulin RIA. Kit a was a fairly precise kit, giving 5.8%of the predicted CV from the precision profile at the intercept of sample A, while kit b gave 9.4% of the CV for the same concentration. The larger predicted CV would cause a larger variation in the assay values.
Another factor to give wide variability may be poor specificity of antibody. Although there was no test of specificity of antibody in the present study, the general experience is that insufficient specificity leads to poor accuracy and possibly to greater variability. Although the present survey made a good inventory of the number of criteria for commercially available kits, the data will not provide a proof that one kit is better than the other. The important thing to remember with regard to the present results is that there is large between-kit variability, and the user must be aware of this.
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